Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human mesothelin chimeric antigen receptor and T cell, preparation method and use thereof

A technology of chimeric antigen receptors and cells, applied in the field of tumor treatment, can solve problems such as limiting the effective activation of specific T cells

Active Publication Date: 2019-07-26
英威福赛生物技术(天津)有限公司
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the immune tolerance environment in the tumor tissue limits the effective activation and function of specific T cells, requiring human intervention in vitro to expand and activate mutant antigen-specific T cells in vitro

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human mesothelin chimeric antigen receptor and T cell, preparation method and use thereof
  • Human mesothelin chimeric antigen receptor and T cell, preparation method and use thereof
  • Human mesothelin chimeric antigen receptor and T cell, preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Example 1. Construction of mesothelin recombinant protein expression plasmid

[0083] The mesothelin cDNA fragment was synthesized in vitro, the HIS tag was added to the tail, and the restriction sites EcoR1 and BglII were introduced at both ends, and cloned into the expression vector pCAGGS to construct a recombinant eukaryotic expression plasmid of the full-length mesothelin protein. The above work was completed by Suzhou Hongxun Company.

[0084] The cDNA sequence of mesothelin recombinant protein is as follows:

[0085] ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTT GCACTTGTCACGAATTCGGAAGTGGAGAAGACAGCCTGTCCTTC AGGCAAGAAGGCCCGCGAGATAGACGAGAGCCTCATCTTCTACA AGAAGTGGGAGCTGGAAGCCTGCGTGGATGCGGCCCTGCTGGCC ACCCAGATGGACCGCGTGAACGCCATCCCCTTCACCTACGAGCA GCTGGACGTCCTAAAGCATAAACTGGATGAGCTCTACCCACAAG GTTACCCCGAGTCTGTGATCCAGCACCTGGGCTACCTCTTCCTCA AGATGAGCCCTGAGGACATTCGCAAGTGGAATGTGACGTCCCTG GAGACCCTGAAGGCTTTGCTTGAAGTCAACAAAGGGCACGAAAT GAGTCCTCAGGTGGCCACCCTGATCGACCGCTTTGTGAAGGGAAGGGGCCAGCTAGA...

Embodiment 2

[0086] Example 2. Expression and purification of mesothelin protein

[0087] 1) Transfection of HEK293T cells (purchased from Shanghai Cell Bank, BNCC338274): 18 hours before transfection, HEK293T cells were transfected at 1.5x10 7 / ml to 30 15cm petri dishes; take 37.5mL DMEM (purchased from Gibco, C11995500CP) (without serum and antibiotics) into a 50mL tube, add 2970μg polyetherimide (PEI) MegaTran 1.0 (purchased from Alfa Aesar, 9002-98-6) mixed; take 37.5mL DMEM (without serum and antibiotics) into a 50mL tube, add mesothelin plasmid DNA 990μg mixed; add PEI / DMEM solution to the prepared DNA solution , Mix quickly and let stand at room temperature for 15 minutes; respectively take 2.5ml of PEI / DNA / DMEM mixture into each petri dish at 37℃, 5% CO 2 Cultivate in the incubator. 6 hours after transfection, carefully aspirate the culture medium, add 25ml of new culture medium DMEM+2% FBS (purchased from Gibco, 10270) + 0.12% double antibody (Penicillin-Streptomycin, purchased from...

Embodiment 3

[0091] Example 3. Preparation and preliminary screening of mesothelin monoclonal antibody

[0092] This part of the work was completed by Nanjing GenScript. The purified full-length mesothelin recombinant protein (hereinafter referred to as mesothelin antigen) obtained in Example 2 was used to immunize B6 / C57 mice according to standard methods. Fusion, screening, etc., obtained 9 monoclonal clones.

[0093] The corresponding cell lines of the fusion plate are 1G7-1, 3A11-1, 3F5-1, 6H12-2, 8C7-1, 8F8-2, 8G8-2, 11E2-2, 11H3-2, and the corresponding monoclonal antibodies are labeled with this .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a human mesothelin chimeric antigen receptor and a T cell, a preparation method and use thereof. The mesothelin chimeric antigen receptor comprises an anti-mesothelin scFv antibody, a CD8 hinge region, a CD28 transmembrane region, a CD3 intracellular region and a 41BB intracellular region. Nucleic acid encoding the receptor, a vector containing the nucleic acid and a host cell comprising the vector are further provided. A method for using the vector for transducing human CD8+ / CD4+ T cells to obtain the CARmesothelin-T cell is further provided. The cell is obtained by genetic modification of the T cell and can be used for treating diseases related to mesothelin expression, especially for specifically recognizing and killing mesothelin expression tumors.

Description

Technical field [0001] The present invention belongs to the technical field of tumor treatment, and specifically relates to a genetic engineering of T cells to express Chimeric Antigen Receptor (CAR) for the treatment of diseases related to the expression of mesothelin. Background technique [0002] In 2011, cancer surpassed heart disease as the world's number one cause of death. The WHO announced in December 2013 that the number of new cancer patients worldwide has exceeded 14 million each year. This is a significant increase compared with the 12.7 million statistics in 2008. During the same period, the death toll of cancer patients also increased, from 7.6 million in the past to 8.2 million. [0003] For tumors, the traditional surgical resection, chemotherapy, and radiation therapy are harmful to normal tissues, have limitations and have limited effects. Targeted therapies that have emerged in recent years are at the cellular and molecular level. Corresponding therapeutic drug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/62C12N15/85C12N5/10C07K19/00A61K35/17A61P35/00
CPCA61K35/17A61P35/00C07K14/7051C07K16/18C07K2317/565C07K2319/02C07K2319/03C12N5/0636C12N2510/00
Inventor 张卫红靳文静陈瑜谭曙光
Owner 英威福赛生物技术(天津)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com